A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Breast Cancer
DRUG: SHR-A1811：Pyrotinib|DRUG: SHR-A1811；Pertuzumab|DRUG: SHR-A1811；Adebrelimab|DRUG: SHR-A1811；Albumin paclitaxel
DLT（Phase I (dose exploration phase) ）, 21 days after the first administration of each subject|AE（Phase I (dose exploration phase) ）, from Day1 to 40 or 90 days after last dose|Incidence and severity of serious adverse events (SAE)（Phase I (dose exploration phase) ）, from Day1 to 40 or 90 days after last dose|Objective response rate（Phase II (efficacy expansion phase)）, Two years after the last subject was enrolled in the group
PK parameter: Cmin of SHR-A1811（Phase I secondary endpoint）, through study completion, an average of 2 years|PK parameter: Cmax of SHR-A1811（Phase I secondary endpoint）, through study completion, an average of 2 years|PK parameter: AUC0-t of SHR-A1811（Phase I secondary endpoint）, through study completion, an average of 2 years|PK parameter: Cmin of Pyrotinib（Phase I secondary endpoint）, through study completion, an average of 2 years|PK parameter: C4h of Pyrotinib（Phase I secondary endpoint）, through study completion, an average of 2 years|PK parameter: Cmin of Adebrelimab（Phase I secondary endpoint）, through study completion, an average of 2 years|Immunogenicity of SHR-A1811（Phase I secondary endpoint）, through study completion, an average of 2 years|Immunogenicity of Adebrelimab（Phase I secondary endpoint）, through study completion, an average of 2 years|Objective Response Rate（Phase I secondary endpoint）, from first dose to disease progression or death, whichever comes first, up to 3 years|Duration of response（Phase I secondary endpoint）, from first dose to disease progression or death, whichever comes first, up to 3 years|Progression Free Survival（Phase I secondary endpoint）, from first dose to disease progression or death, whichever comes first, up to 3 years|AE（Phase II secondary study endpoint）, from Day1 to 40 or 90 days after last dose|Incidence and severity of serious adverse events (SAE)（Phase II secondary study endpoint）, from Day1 to 40 or 90 days after last dose|PK parameter: Cmin, Cmax, and AUC0-t of SHR-A1811（Phase II secondary study endpoint）, through study completion, an average of 2 years|PK parameter: Cmin, C4h of Pyrotinib:（Phase II secondary study endpoint）, through study completion, an average of 2 years|PK parameter: Cmin of Adebrelimab（Phase II secondary study endpoint）, through study completion, an average of 2 years|Immunogenicity of SHR-A1811（Phase II secondary study endpoint）, through study completion, an average of 2 years|Immunogenicity of Adebrelimab（Phase II secondary study endpoint）, through study completion, an average of 2 years|Duration of response（Phase II secondary study endpoint）, from first dose to disease progression or death, whichever comes first, up to 3 years|Progression Free Survival（Phase II secondary study endpoint）, from first dose to disease progression, or death, whichever comes first, up to 3 years|Event-Free Survival Rate（Phase II secondary study endpoint）, from first dose to disease progression, disease recurrence, or death, whichever comes first, up to 3 years
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.